https://www.thebodypro.com/category/tenofovir-tdf-viread/tag/bone

The Latest

Promo Image

This Week in HIV Research: A New Frontier in Organ Transplantation

HIV-positive donor, HIV-negative recipient; continuum of care after incarceration in U.S.; reduced bone mineral density among men with HIV under 50; discouraging anti-inflammatory findings for an antiplatelet agent.

Promo Image

Late 2017 HIV Conferences Focus on Antiretrovirals and Comorbidities

2017 may be winding down, but even as the year wanes, we’ve seen significant new HIV research featured in major scientific conferences in the U.S. and Europe. IDWeek, most recently held in San Diego in early October 2017, is an annual infectious disease...

Tenofovir (TDF) Not Tied to Bone Fractures in French Case-Control Study Img

Tenofovir (TDF) Not Tied to Bone Fractures in French Case-Control Study

The findings could inform the debate on the merits of TDF, which is available in many regions as a less-costly generic, versus the more recently approved prodrug tenofovir alafenamide (TAF).

Kidney and Bone Markers Improve After TDF-to-TAF Switch in People 50 or Older Img

Kidney and Bone Markers Improve After TDF-to-TAF Switch in People 50 or Older

Switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) improved kidney and bone markers in a study focused on people 50 years old or older.

Tenofovir-Containing ART Reduces Bone Mineral Density in Breast-Feeding Women: Results From IMPAACT P1084s Img

Tenofovir-Containing ART Reduces Bone Mineral Density in Breast-Feeding Women: Results From IMPAACT P1084s

Tenofovir DF-containing ART decreases bone mineral density in HIV-positive, breast-feeding women, according to findings presented at the 8th International Workshop on HIV Paediatrics.

Switch From TDF to TAF Tied to Better Bone Mineral Density and Bone Markers Img

Switch From TDF to TAF Tied to Better Bone Mineral Density and Bone Markers

Bone mineral density (BMD) improved in the 96 weeks after patients switched from a combination containing tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) as part of the single-tablet regimen elvitegravir/cobicistat/emtricitabine/TA...

No Effect of Tenofovir on Infant Bone Mineral Content in African Study Img

No Effect of Tenofovir on Infant Bone Mineral Content in African Study

A report from the PROMISE study showed no adverse bone mineral effect, linked to maternal tenofovir disoproxil fumarate (TDF), in exposed infants.

Single-Tablet HIV Regimen Containing Tenofovir Alafenamide Improves Bone and Kidney Safety Img

Single-Tablet HIV Regimen Containing Tenofovir Alafenamide Improves Bone and Kidney Safety

A new single-tablet HIV regimen containing tenofovir alafenamide (TAF) offered better bone and kidney safety, according to a study presented at ICAAC/ICC 2015.

Tenofovir Alafenamide (TAF) Gentler on the Bones and Kidneys Img

Tenofovir Alafenamide (TAF) Gentler on the Bones and Kidneys

The new formulation of tenofovir, tenofovir alafenamide (TAF), was associated with less harm to bones and kidneys than the older formulation, tenofovir disoproxil fumarate (TDF, Viread).